Article in BioCentury: Adrecizumab shows apparent mortality benefit in septic shock trial
April 2021, by Stephen Hansen
April 2021, by Stephen Hansen
September 2020, by Cormac Sheridan
August 2020, by Cormac Sheridan Read the full article here.
February 2020, by Michael Flanagan
February 2020, by Cormac Sheridan
October 2019, by Lauren Martz and Inhua Muijrers-Chen, Associate Editors
Read the full article about Adrenomed on page 104 of the GoingPublic Special Issue “Biotechnologie 2019” (Article in German). Illustration: Adrenomed AG
April 2019 by Cormac Sheridan, Staff Writer.
BIO-Europe Spring 2019: Adrenomed’s Hein on sepsis and beyond. “We don’t want sepsis to be the number one killer in the USA’s ICU anymore. We want to substantially cut the mortality rate” said Adrenomed CBO
Published in the January 2019 edition of MedNous, a publication of Evernow Publishing Ltd.
By loading the map, you agree to Google's privacy policy.
Learn more
© 2024 AdrenoMed AG | Imprint/Impressum | Legal Notice/Datenschutzerklärung | Expanded Access Policy